University of Maryland Baltimore
Welcome,         Profile    Billing    Logout  
 77 Trials 
101 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lee, Seung Sei
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Canada, Japan, US, RoW
LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/23
05/27
NCT05936658: [18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer

Recruiting
3
89
RoW
[F-18]Florastamin
FutureChem
High Risk Prostate Carcinoma
12/24
12/24
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
12/25
07/26
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
Jun 2022 - Jun 2022: Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/refractory Diffuse Large B-cell Lymphoma
12/24
12/25
PLATINUM, NCT05338619: A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy

Recruiting
2
77
RoW
Lazertinib, LECLAZA
Sung Yong Lee, Yuhan Corporation
Non-small Cell Lung Cancer Stage III, EGFR Positive Non-small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer
03/26
03/26
NCT05506007: A Clinical Trial to Compare the Safety, Tolerability, and PK Properties of DA-5216 and DA-5216-R and to Evaluate the Food Effect on DA-5216.

Recruiting
1
88
RoW
DA-5216, DA-5216-R
Dong-A ST Co., Ltd.
Healthy
10/22
10/22
NCT05992428: Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy Adults

Completed
1
37
RoW
DA-8010 5mg, Paroxetine 20mg, Mirabegron 50mg
Dong-A ST Co., Ltd.
Healthy
11/23
12/23
NCT05321147: Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2

Completed
1
20
US, RoW
lacutamab, IPH4102
Innate Pharma
Peripheral T Cell Lymphoma
11/23
02/24
NCT05703282: A Study to Assess the Safety and Pharmacokinetics of AD-104-A

Completed
1
32
RoW
AD-104-A
Addpharma Inc.
Hyperlipidemias
04/24
04/24
NCT05991401: Evaluate the Effect of Clarithromycin/Rifampicin on the Pharmacokinetics of DA-8010 in Healthy Adults

Completed
1
18
RoW
DA-8010 5mg, Clarithromycin 500mg, Rifampicin 600mg
Dong-A ST Co., Ltd.
Healthy
11/23
11/23
NCT06164834: Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Subjects

Not yet recruiting
1
48
RoW
Clopidogrel 75 mg, Plavix, Tegoprazan 25 mg, K-CAB, Esomeprazole 20mg, Nexium
HK inno.N Corporation
Healthy
11/24
11/24
NCT06391827: A Study to Evaluate Safety, Tolerability, and PK of DA-7503 in Healthy Adult and Elderly Participants

Not yet recruiting
1
72
RoW
DA-7503 Single dose, DA-7503 Multiple dose, Placebo Single dose, Placebo Multiple dose
Dong-A ST Co., Ltd.
Healthy
05/25
05/25
NCT06736912: This Study Aims to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties and Food Effect of IN-114199 in Healthy Participants

Not yet recruiting
1
80
RoW
IN-114199 2.5mg or placebo, IN-114199 10mg or placebo, IN-114199 20mg or placebo, IN-114199 40mg or placebo, IN-114199 5mg or placebo
HK inno.N Corporation
Chronic Idiopathic Constipation
08/25
11/25
NCT05365659: IKS03 in Patients with Advanced B Cell Non-Hodgkin Lymphomas

Recruiting
1
140
Europe, Canada, US, RoW
IKS03
Iksuda Therapeutics Ltd.
B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, B-cell Lymphoma
09/25
09/27
C1763102, NCT05602363: AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Recruiting
1
120
US
Docirbrutinib, AS-1763
Carna Biosciences, Inc.
B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
09/27
09/27
NCT05493904: PREcise Percutaneous Coronary Intervention for Stent OptimizatION in Treatment of COMPLEX Lesion (PRECISION-COMPLEX)

Recruiting
N/A
320
RoW
OCT-guided PCI, Angiography-guided PCI, Drug-eluting stent
Chonnam National University Hospital, Abbott Medical Devices
Coronary Artery Disease, Angina Pectoris
08/24
12/26
MANTRA, NCT05002543: CORCYM Mitral, Aortic aNd Tricuspid Post-maRket Study in a reAl-world Setting

Recruiting
N/A
2150
Europe, Canada, US, RoW
Corcym S.r.l
Cardiac Valve Disease
08/25
12/35
CMD-MINOCA, NCT05272618: Coronary Microvascular Dysfunction Assessments in Myocardial Infarction With Non-Obstructive Coronary Arteries

Recruiting
N/A
150
RoW
Intravascular imaging (OCT), Invasive physiologic assessment (FFR, CFR, IMR), or Non-invasive physiologic assessment (N-13 ammonia PET)
Chonnam National University Hospital, Korean Cardiac Research Foundation, Abbott
Myocardial Infarction, Coronary Microvascular Dysfunction, Vasospasm, Coronary
12/26
12/27
ASSIST, NCT05529459: Anatomic Versus Physiologic Guidance for Complete Revascularization With DES Eluting in Patients With CAD

Recruiting
N/A
2400
RoW
Percutaneous Coronary Intervention
Seung-Whan Lee, M.D., Ph.D., Biotronik Korea Co., Ltd
Coronary Disease
12/26
07/30
Fasano, Alessio
NCT05636293: Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission

Recruiting
2
30
US
Ritlecitinib, Placebo, Gluten
Massachusetts General Hospital, Pfizer
Celiac Disease
08/25
08/25
Gammie, James S
ICE-AFIB, NCT03732794: AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment

Active, not recruiting
N/A
150
US
AtriCure CryoICE & AtriClip LAA Exclusion
AtriCure, Inc.
Atrial Fibrillation (AF), Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation
06/24
06/26
APOLLO, NCT03242642: Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Recruiting
N/A
1056
Europe, Canada, US
Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
Medtronic Cardiovascular
Mitral Valve Regurgitation
10/26
09/36
Reed, Robert
ALAMO, NCT05050955: AlloSure Lung Assessment and Metagenomics Outcomes Study

Recruiting
N/A
500
Canada, US
CareDx
Lung Transplant Infection, Lung Transplant; Complications, Lung Transplant Failure and Rejection
12/28
12/28
Taylor, Bradley K
TRIOMPHE, NCT04471909: NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness

Recruiting
N/A
110
US, RoW
NEXUS Aortic Stent Graft System
Endospan Ltd.
Aortic Dissection, Aortic Aneurysm, Intramural Hematoma, Penetrating Aortic Ulcer
11/24
10/29
RelayBranch, NCT03214601: Early Feasibility Study of the Thoracic Stent-Graft System

Active, not recruiting
N/A
30
US
penetrating atherosclerotic ulcer, aorta branch cardiovascular implant, Relay Branch System, system, endovascular graft, aortic aneurysm treatment
Bolton Medical
Thoracic Aorta Aneurysm, Aneurysm, Ruptured, Aortic Aneurysm
09/23
08/28
STAR-T, NCT04976530: Safe and Timely Antithrombotic Removal - Ticagrelor

Completed
N/A
140
Canada, US
DrugSorb-ATR system, Sorbent hemoperfusion system, Sham comparator
CytoSorbents, Inc
Hemorrhage, Surgical, Blood Loss, Surgical, Blood Loss, Postoperative, Hemorrhage Postoperative
08/23
08/23
SSB 11-02, NCT02777528: Evaluation of the GORE® TAG® Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta (Zone 0/1)

Active, not recruiting
N/A
150
Japan, US
GORE® TAG® Thoracic Branch Endoprosthesis, Revascularization Procedure
W.L.Gore & Associates
Aortic Aneurysm, Thoracic, Aorta, Lesion
03/24
03/28
SUMMIT, NCT03433274: Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation

Recruiting
N/A
958
Canada, US
Tendyne Mitral Valve System, MitraClip System
Abbott Medical Devices
Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease
05/24
06/28
NCT04482062: TRISCEND II Pivotal Trial

Active, not recruiting
N/A
1070
Europe, US
Edwards EVOQUE System, Transcatheter tricuspid valve replacement, Optimal Medical Therapy
Edwards Lifesciences
Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases, Cardiovascular Diseases, Heart Failure
06/24
12/29
APOLLO, NCT03242642: Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Recruiting
N/A
1056
Europe, Canada, US
Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
Medtronic Cardiovascular
Mitral Valve Regurgitation
10/26
09/36
Nangia, Chaitali
BRIA-ABC, NCT06072612: Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Recruiting
3
404
US
SV-BR-1-GM, Part of the Bria-IMT regimen, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice
BriaCell Therapeutics Corporation
Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
06/25
12/25
QUILT-88, NCT04390399: Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Checkmark Data from QUILT 88 trial in combination anti–PD-L1 NK cell therapy in advanced pancreatic cancer at ASCO 2022
Jun 2022 - Jun 2022: Data from QUILT 88 trial in combination anti–PD-L1 NK cell therapy in advanced pancreatic cancer at ASCO 2022
Hourglass Jul 2021 - Sep 2021 : Anticipated enrollment of Cohort C in metastatic 3L pancreatic cancer
Active, not recruiting
2
328
US
N-803, Aldoxorubicin HCl, PD-L1 t-haNK, Nab-paclitaxel, Gemcitabine, Cyclophosphamide, 5-Fluorouracil, Leucovorin, SBRT, Irinotecan liposome
ImmunityBio, Inc.
Pancreatic Cancer
10/25
10/25
NCT06710288: A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer

Recruiting
2
20
US
Gemcitabine, gemcitabine hydrocholoride, Gemzar, N-803, M-CENK, Autologous Memory Cytokine Enriched Natural Killer
ImmunityBio, Inc.
Platinum-resistant Ovarian Cancer
05/27
05/27
BRI-ROL-001, NCT03328026: Combination Study of SV-BR-1-GM With Retifanlimab

Checkmark In combination with Bria-IMT for advanced breast cancer
Sep 2019 - Sep 2019: In combination with Bria-IMT for advanced breast cancer
Checkmark Safety data in combination with Bria-IMT
Dec 2018 - Dec 2018: Safety data in combination with Bria-IMT
Checkmark Anticipated efficiency data in combination with Bria-IMT
More
Enrolling by invitation
1/2
36
US
SV-BR-1-GM, Low dose cyclophosphamide, Cytoxan, Interferon Inoculation, retifanlimab, INCMGA00012
BriaCell Therapeutics Corporation, LumaBridge
Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer, Breast Cancer Metastatic
11/25
11/28
Amelia-1, NCT05455619: Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Women With a PI3K Alteration and HR+/Her2- Breast Cancer

Recruiting
1/2
52
US
Evexomostat, SDX-7320
SynDevRx, Inc.
HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer
03/26
09/26
NCT03743298: Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma

Recruiting
1b
20
US
AV-MEL-1
Aivita Biomedical, Inc.
Metastatic Melanoma
05/24
05/26
NCT04942054: A Study in Patients With Advanced Breast Cancer

Terminated
1
9
US, RoW
Part 1, Part 2, Part 3
Sun Pharma Advanced Research Company Limited
HER2-negative Breast Cancer, Advanced Breast Cancer, Hormone Receptor-positive Breast Cancer
02/23
02/23
DRAGON, NCT04291079: SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors

Active, not recruiting
1
112
US, RoW
SRK-181, anti-PD-(L)1 antibody therapy
Scholar Rock, Inc.
Cancer
12/24
12/24
NCT04898543: QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors

Recruiting
1
50
US
M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B), N-803 (Cohort 2 part B), Apheresis collection of MNCs (part A)
ImmunityBio, Inc.
Metastatic Solid Tumor
03/25
03/25
QUILT-3.100, NCT05976828: IBRX-042 in Participants with HPV-Associated Tumors

Recruiting
1
12
US
IBRX-042, IBRX-042 (hAd5-HPV E6.ETSD-IRES-E7.ETSD Vaccine)
ImmunityBio, Inc.
HPV-Related Carcinoma
09/25
08/33
NCT04595838: A Trial Assessing Chemo Mouthpiece Device With Best Supportive Care for Symptoms of Chemotherapy-Induced Oral Mucositis

Completed
N/A
176
US
Chemo Mouthpiece, Oral cryotherapy delivery device, Best Supportive Care only
Chemo Mouthpiece
Oral Mucositis
05/23
05/23
Chumsri, Saranya
ELU-FRα-1, NCT05001282: A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Terminated
1/2
79
US
ELU001, FA-CDC
Elucida Oncology
Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer, Ovary Cancer, Ovary Neoplasm, Ovary Disease, Ovary Metastasis, Ovarian Diseases, Ovarian Cancer Stage, Ovarian Epithelial Cancer, Ovarian Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Neoplasm Epithelial, Ovarian Cancer Recurrent, Endometrial Diseases, Endometrial Adenocarcinoma, Endometrial Carcinosarcoma, Endometrial Clear Cell Adenocarcinoma, Endometrioid Adenocarcinoma, Endometrial Neoplasms, Endometrial Cancer Recurrent, Endometrioid Tumor, Fallopian Tube Cancer, Peritoneal Cancer
06/24
06/24
BRI-ROL-001, NCT03328026: Combination Study of SV-BR-1-GM With Retifanlimab

Checkmark In combination with Bria-IMT for advanced breast cancer
Sep 2019 - Sep 2019: In combination with Bria-IMT for advanced breast cancer
Checkmark Safety data in combination with Bria-IMT
Dec 2018 - Dec 2018: Safety data in combination with Bria-IMT
Checkmark Anticipated efficiency data in combination with Bria-IMT
More
Enrolling by invitation
1/2
36
US
SV-BR-1-GM, Low dose cyclophosphamide, Cytoxan, Interferon Inoculation, retifanlimab, INCMGA00012
BriaCell Therapeutics Corporation, LumaBridge
Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer, Breast Cancer Metastatic
11/25
11/28
Deeley, Maura
SPRAY-CB, NCT03893370: RejuvenAir® System Trial for COPD With Chronic Bronchitis

Active, not recruiting
N/A
210
Europe, US
RejuvenAir System, Sham Control Procedure
CSA Medical, Inc.
Chronic Bronchitis
05/25
09/26
Almardawi, Ranyah
NCT04579692: MR Guided Focused Ultrasound (FUS) for the Treatment of Trigeminal Neuralgia

Recruiting
N/A
10
US
ExAblate Transcranial treatment, The ExAblate® MR guided focused ultrasound system
University of Maryland, Baltimore, Focused Ultrasound Foundation, InSightec
Trigeminal Neuralgia
06/25
06/25
Coordinator, Research
CAMPLIFE, NCT06562296: Study Evaluating Several CAMPs in Nonhealing Diabetic Foot and Venous Leg Ulcers

Recruiting
4
292
US
Amnion-Intermediate-Chorion, AIC, Amnion-Chorion-Amnion, ACA, Standard of Care, SOC
Cellution Biologics, SerenaGroup, Inc., LifeCell
Diabetic Foot Ulcer, Venous Leg Ulcer
12/26
07/27
NCT05078827: Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis

Completed
3
458
US
Test Product (A): Fluorouracil Cream, 5% topical cream, Experimental, Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A., Active Comparator, Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India, Placebo Comparator
Encube Ethicals Pvt. Ltd., CBCC Global Research
Actinic Keratoses
11/22
12/22
ReMMi-D, NCT05853900: Study of Two Digital Therapeutics for the Prevention of Episodic Migraine

Completed
3
558
US
ReMMi-D Digital Therapeutic
Click Therapeutics, Inc.
Migraine, Episodic Migraine, Headache, Headache, Migraine
05/24
05/24
OPERA-T, NCT05238116 / 2021-004554-32: Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis ( Study)

Recruiting
3
123
Europe, Canada, US, RoW
PC945, Placebo
Pulmocide Ltd
Refractory IPA
03/26
04/26
NCT06004388: Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)

Completed
3
110
US
Click Digital Therapeutic
Click Therapeutics, Inc.
Migraine, Episodic Migraine, Headache, Headache, Migraine
05/24
06/24
CONVOKE, NCT05838625: Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia

Recruiting
3
432
US
Digital Therapeutic
Click Therapeutics, Inc., Boehringer Ingelheim
Schizophrenia
06/25
07/25
NCT06067984: An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia

Active, not recruiting
3
75
US
Study App
Click Therapeutics, Inc., Boehringer Ingelheim
Schizophrenia, Negative Symptoms in Schizophrenia
04/25
05/25
NCT06365437: A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation

Completed
2
33
Europe
TCD601, Siplizumab, Tacrolimus (TAC), Corticosteroids (CS), Mycophenolate Mofetil (MMF), ATG
ITB-Med LLC
Kidney Transplantation
12/24
12/24
PHYOX8, NCT05001269 / 2021-001083-16: Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function

Recruiting
2
25
Europe, Canada, Japan, US, RoW
nedosiran, DCR-PHXC
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Primary Hyperoxaluria, Primary Hyperoxaluria Type 1, Primary Hyperoxaluria Type 2, Primary Hyperoxaluria Type 3
12/24
12/24
CHASE, NCT05727878: Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED

Recruiting
2
90
US, RoW
KPI-012, KPI-012 Vehicle
Combangio, Inc, Kala Pharmaceuticals, Inc.
Persistent Corneal Epithelial Defect
03/25
10/25
NCT05733546: A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder

Recruiting
2
102
US
Psilocybin, COMP360
COMPASS Pathways
Major Depressive Disorder
10/24
11/24
NCT04270175: Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Recruiting
2
21
US
Daratumumab SC, Faspro, Pomalidomide, Dexamethasone
Weill Medical College of Cornell University, Janssen Scientific Affairs, LLC
Amyloid, AL Amyloidosis, Refractory AL Amyloidosis
12/25
12/29
NCT04803058: A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)

Recruiting
2
18
US, RoW
TCD601
ITB-Med LLC
Kidney Transplantation
03/27
03/30
STRIDE, NCT06025110: A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients

Active, not recruiting
2
96
Europe
TCD601, Placebo
ITB-Med LLC
Diabetes Mellitus, Type 1
01/25
01/25
ASCEND, NCT05669001: A Study of TCD601 in de Novo Renal Transplant Recipients

Recruiting
2
90
US
TCD601, siplizumab, belatacept, ATG, antithymocyte globulin, TAC, tacrolimus, MPA, mycophenolic acid, Corticosteroids
ITB-Med LLC
Renal Transplantation
07/25
10/26
NCT04311632: A Dose Escalation Study in de Novo Renal Transplantation

Completed
2
13
US
TCD601, Tacrolimus (TAC), Corticosteroids (CS), Mycophenolate Mofetil (MMF), ATG
ITB-Med LLC
Kidney Transplantation
10/23
10/23
NCT04464980: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Recruiting
2
2190
US
SL-BUP, sublingual buprenorphine, Suboxone, XR-BUP, extended-release buprenorphine, CAM2038, Brixadi, XR-NTX, extended-release naltrexone, Vivitrol, MM, MMR, MMD
NYU Langone Health, New York State Psychiatric Institute, Columbia University, Harvard Medical School (HMS and HSDM), Mclean Hospital, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC
Opioid Use Disorder (OUD)
07/26
12/26
NCT04803006: A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)

Recruiting
2
18
US
TCD601
ITB-Med LLC
Kidney Transplantation
07/27
07/30
AURORA, NCT06453668: A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients

Active, not recruiting
1
48
Europe
TCD601, siplizumab
ITB-Med LLC
ALS
11/26
11/26
PBL-0405-01, NCT06273852: A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors

Recruiting
1
15
US
PBA-0405, PB004.22.0405.aF
Pure Biologics S.A., Presage Biosciences
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer
03/25
03/25
MST01-AZN-05, NCT06366451: PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC

Recruiting
1
15
US
Rilvegostomig, AZD2936, Volrustomig, MEDI5752, Sabestomig, AZD7789, Pembrolizumab, Keytruda, MK-3475
Presage Biosciences, AstraZeneca
Head and Neck Squamous Cell Carcinoma
12/24
03/25
OP-1250-003, NCT05508906: Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus

Recruiting
1
155
US, RoW
OP-1250, Ribociclib, KISQALI®, Alpelisib, PIQRAY®, Everolimus
Olema Pharmaceuticals, Inc., Novartis
Metastatic Breast Cancer, Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Breast Cancer
05/26
06/26
NCT06798454: Single Ascending Dose Study to Evaluate Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 in Healthy Subjects and Patients (PBC/PSC)

Recruiting
1
30
RoW
PVT201, Navacim, Placebo, normal saline, 0.9% NaCl
Parvus Therapeutics, Inc., Avance Clinical Pty Ltd.
Primary Biliary Cholangitis (PBC)
02/25
02/25
NCT04541108: Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Recruiting
1
15
US
Rilvegostomig, AZD2936, Volrustomig, MEDI5752, Sabestomig, AZD7789, Pembrolizumab, Keytruda, MK-3475
Presage Biosciences, Merck Sharp & Dohme LLC
Solid Tumor
12/31
12/31
NCT06802328: Treatment Protocol: Intermediate-Size Patient Population Expanded Access

Available
N/A
US
Foralumab TZLS-401 50 µg
Tiziana Life Sciences LTD
Non-Active Secondary Progressive Multiple Sclerosis
 
 
NCT06136936: A Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia

Completed
N/A
53
US
CT-156-C-001
Click Therapeutics, Inc., Boehringer Ingelheim
Schizophrenia
01/24
02/24
NCT05222581: Engineering Evaluation of a Breast Pump Device

Recruiting
N/A
20
US
Prototypes of breast shield and Freedom Double Electric Breast Pump
Momtech Inc.
Healthy, Breast Pumping
09/24
11/24
NCT06136923: An Exploratory Study to Evaluate Attention Biases in Adults With Multiple Sclerosis, Breast Cancer, and Lung Cancer

Completed
N/A
194
US
CT-100-D-004-A, CT-100-D-004-B
Click Therapeutics, Inc.
Multiple Sclerosis, Lung Cancer, Breast Cancer
04/24
05/24
LOCAL, NCT04968847: FemaSeed Artificial Insemination Trial

Completed
N/A
314
US
FemaSeed Localized Directional Insemination
Femasys Inc.
Infertility, Male Factor
12/23
04/24
CT-100-D-003, NCT06275659: An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis

Active, not recruiting
N/A
120
US
CT-100-004-A, CT-100-004-B
Click Therapeutics, Inc.
Psoriasis, Atopic Dermatitis
02/24
03/24
NCT05119842: APrevent-VOIS-Implant-002 - a Two-Part, Open-Label, Non-Randomized Multicenter Study

Recruiting
N/A
30
Europe, US
APrevent® VOIS-Implant
APrevent Biotech GmbH
Paralysis, Unilateral, Vocal Cord
09/25
09/26
Lublin, NCT06217081: 3M™ Topical Tissue Adhesive Versus Commercially Available Tissue Adhesive for the Closure of Lacerations and Incisions

Recruiting
N/A
452
US
3M Topical Tissue Adhesive, Histoacryl® Blue Topical Skin Adhesive
Solventum US LLC, United States Department of Defense, The University of Texas Health Science Center at San Antonio, 3M
Trauma-related Wound, Surgical Incision, Surgical Wound, Laceration
11/25
12/25
CoMind EFS, NCT06368648: CoMind Early Feasibility Study

Recruiting
N/A
581
US
CoMind Technologies Limited, Lindus Health
Intracranial Pressure, Intracranial Pressure Changes, Traumatic Brain Injury, Intracerebral Hemorrhage, Encephalitis, Encephalopathy, Hydrocephalus, Stroke, Autoregulation
10/25
10/25
NCT05006404: Autus Valve Pivotal Study

Recruiting
N/A
50
US
Pulmonary Valve Replacement Surgery
Autus Valve Technologies, Inc.
Congenital Heart Disease
08/26
02/36
MASTR, NCT05243966: Myriad™ Augmented Soft Tissue Reconstruction Registry

Recruiting
N/A
800
US
Myriad Matrix™ and Myriad Morcells™
Aroa Biosurgery Limited
Abdominal Wound Dehiscence, Necrotizing Soft Tissue Infection, Lower Extremity Wound, Pilonidal Sinus, Anal Fistula, Hidradenitis Suppurativa, Pressure Injury
01/28
01/29
NCT06770998: A Study of a Novel EEG Neurofeedback System for PTSD Treatment

Not yet recruiting
N/A
250
US
EEG-neurofeedback training, Prism training, amyg-EFP training, active Prism training, Sham training, sham Prism training
Foundation for Atlanta Veterans Education and Research, Inc., GrayMatters Health Ltd., Rochester Institute of Technology, New York University Grossman School of Medicine, Atlanta VA Medical Center, Birmingham VA Health Care System, Ralph H. Johnson VA Medical Center, VA Boston Healthcare System, CTP Inc, BioStats Statistical Consulting Ltd, ShareCRF, United States Department of Defense
Stress Disorders, Post-Traumatic
06/27
08/27
PHONES, NCT04662320: Promoting Healing of Nerves Through Electrical Stimulation

Active, not recruiting
N/A
100
US
Checkpoint BEST System, Brief Electrical Stimulation (BES) Therapy
Checkpoint Surgical Inc., Congressionally Directed Medical Research Programs
Cubital Tunnel Syndrome, Nerve Compression, Nerve Injury, Ulnar Neuropathies
12/25
12/25
FINALE, NCT05977751: Prospective Multi-Center Trial for FemBloc Permanent Birth Control

Recruiting
N/A
573
US
FemBloc
Femasys Inc.
Contraception
12/29
06/31
PHINEST, NCT05884125: Promoting Healing of Injured Nerves With Electrical Stimulation Therapy

Recruiting
N/A
60
US
Checkpoint BEST System, Brief Electrical Stimulation (BES) Therapy
Checkpoint Surgical Inc., Congressionally Directed Medical Research Programs
Nerve Injury, Peripheral Nerve Injuries, Peripheral Nerve Injury Upper Limb, Nerve Palsy
06/27
06/27
NCT05678530: Observational, Non-Interventional Study Supporting Validation of VO2Max Estimation Methods Using Results in Patients Receiving Standard of Care Cardiopulmonary Exercise Tests (CPET)

Recruiting
N/A
400
Canada, US
Prolaio
Cardiopulmonary
06/25
06/25
Akbari, Freshta
RECOVER, NCT04629105: Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B

Active, not recruiting
1
70
US
Longeveron Mesenchymal Stem Cells (LMSCs), Placebo
Longeveron Inc.
ARDS, Human, Covid19
06/24
07/25
ICE-AFIB, NCT03732794: AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment

Active, not recruiting
N/A
150
US
AtriCure CryoICE & AtriClip LAA Exclusion
AtriCure, Inc.
Atrial Fibrillation (AF), Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation
06/24
06/26
Harrington, Thelma
NCT04524962: Study of Descartes-30 in Acute Respiratory Distress Syndrome

Terminated
1
12
US
Descartes 30
Cartesian Therapeutics, National Heart, Lung, and Blood Institute (NHLBI)
Acute Respiratory Distress Syndrome, Covid19
09/22
09/23
Toursavadkohi, Shahab
TRIOMPHE, NCT04471909: NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness

Recruiting
N/A
110
US, RoW
NEXUS Aortic Stent Graft System
Endospan Ltd.
Aortic Dissection, Aortic Aneurysm, Intramural Hematoma, Penetrating Aortic Ulcer
11/24
10/29
TAMBE, NCT05442489: Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of the Thoracoabdominal and Pararenal Aortic Aneurysms

Approved for marketing
N/A
US
GORE Excluder Thoracoabdominal Branch Endoprosthesis, TAMBE
W.L.Gore & Associates
Thoracoabdominal Aneurysm
 
 
TAMBE, NCT03728985: Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms

Active, not recruiting
N/A
102
Europe, US
GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis, TAMBE
W.L.Gore & Associates
Thoracoabdominal Aortic Aneurysm
01/23
09/26
Pan, Xiaoou
ARTEST, NCT04869943 / 2021-002176-39: Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

Terminated
3
52
Europe, US, RoW
Enobosarm, VERU-024, Exemestane, Mestane
Veru Inc.
Metastatic Breast Cancer
01/24
01/24
CG03, NCT03949283: Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer

Active, not recruiting
3
150
US
ChemoID Assay, Chemotherapeutic drug cytotoxicity assay of cancer stem cells (CSCs), Standard Chemotherapy, Chemotherapy
Cordgenics, LLC
Recurrent Ovarian Carcinoma, Platinum-resistant Ovarian Cancer
06/24
12/24
Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer ().

Recruiting
3
560
Europe, Canada, Japan, US, RoW
sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel
Seagen Inc.
Carcinoma, Non-Small-Cell Lung
07/26
07/28
BDTX-1535-101, NCT05256290: Phase 1/2 Study of BDTX-1535 in Patients with Glioblastoma or Non-Small Cell Lung Cancer with EGFR Mutations

Recruiting
1/2
200
US
BDTX-1535 monotherapy
Black Diamond Therapeutics, Inc.
Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, NSCLC, Advanced Lung Carcinoma, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation
07/25
06/26
Amelia-1, NCT05455619: Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Women With a PI3K Alteration and HR+/Her2- Breast Cancer

Recruiting
1/2
52
US
Evexomostat, SDX-7320
SynDevRx, Inc.
HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer
03/26
09/26
Watkins, Runa
NCT05480761: 7-Day Trial of Sucraid for Alleviating CSID Symptoms in Subjects With Low, Moderate, and Normal Sucrase Levels

Recruiting
4
1100
US
Sucraid (sacrosidase) Oral Solution 8500 IU/mL, Sucraid, Sacrosidase
QOL Medical, LLC
Congenital Sucrase-Isomaltase Deficiency, CSID, Sucrase Isomaltase Deficiency
08/24
12/24
Weir, Valerie
NCT05480761: 7-Day Trial of Sucraid for Alleviating CSID Symptoms in Subjects With Low, Moderate, and Normal Sucrase Levels

Recruiting
4
1100
US
Sucraid (sacrosidase) Oral Solution 8500 IU/mL, Sucraid, Sacrosidase
QOL Medical, LLC
Congenital Sucrase-Isomaltase Deficiency, CSID, Sucrase Isomaltase Deficiency
08/24
12/24
Mario, Tano
NCT05480761: 7-Day Trial of Sucraid for Alleviating CSID Symptoms in Subjects With Low, Moderate, and Normal Sucrase Levels

Recruiting
4
1100
US
Sucraid (sacrosidase) Oral Solution 8500 IU/mL, Sucraid, Sacrosidase
QOL Medical, LLC
Congenital Sucrase-Isomaltase Deficiency, CSID, Sucrase Isomaltase Deficiency
08/24
12/24
 

Download Options